| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170652-100μg | 100μg | In stock | $79.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2SA; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Utomilumab (anti-TNFRSF9) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to TNFRSF9, >95%, high purity, Human IgG2SA |
|---|---|
| Synonyms | 4 1BB antibody | 4 1BB ligand receptor antibody | 4-1BB ligand receptor antibody | 4-1BB Ligand Receptor T Cell antibody | 4-1BB, mouse, homolog of antibody | Antigen 4-1BB Homolog antibody | CD 137 antibody | CD137 antibody | CD137 antigen antibody | CDw |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC), See COA |
| Host species | Human |
| Specificity | TNFRSF9 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | AGONIST |
| Mechanism of action | Antibody of 4-1BB |
| Product Description | PurityUtomilumab is a humanized IgG2 mAb agonist that targets the T-cell co-stimulatory receptor 4-1BB/CD137. Utomilumab can be used in relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphoma (NHL) studies. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG2SA |
| Light Chain Type | lambdaC2 |
| SDS-PAGE | 28.6 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 171.1 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 1417318-27-4 |
Utomilumab (anti-TNFRSF9) (Ab170652) - ELISA
Immobilized Human TNFRSF9/ 4-1BB/ CD137-his at 2.0 μg/mL can bind Utomilumab (anti-TNFRSF9) (Ab170652) with the EC₅₀ of 6.92 ng/mL.
Utomilumab (anti-TNFRSF9) (Ab170652) - SEC
The purity of Utomilumab (anti-TNFRSF9) (Ab170652) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IMGT/mAb-DB | 657 |
|---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0303717 | Certificate of Analysis | Mar 26, 2024 | Ab170652 |
| ZJ24F0303716 | Certificate of Analysis | Mar 26, 2024 | Ab170652 |
| ZJ24F0303715 | Certificate of Analysis | Mar 26, 2024 | Ab170652 |
| 1. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, Bergqvist S, Baxi SM, Rohner A, Shen AC et al.. (2012) Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity.. Cancer Immunol Immunother, 61 (10): (1721-33). [PMID:22406983] [10.1021/op500134e] |
| 2. Mittal P, Abblett R, Ryan JM, Hagymasi AT, Agyekum-Yamoah A, Svedova J, Reiner SL, St Rose MC, Hanley MP, Vella AT et al.. (2018) An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.. J Immunol, 200 (4): (1513-1526). [PMID:29305435] [10.1021/op500134e] |
| 3. Zhou, Z Z and 6 more authors.. (1995) Characterization of human homologue of 4-1BB and its ligand.. Immunology letters, [PMID:7622190] |
| 4. Alderson, M R MR and 9 more authors.. (1994) Molecular and biological characterization of human 4-1BB and its ligand.. European journal of immunology, [PMID:8088337] |
| 5. Schwarz, H H, Tuckwell, J J and Lotz, M M.. (1993) A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family.. Gene, (8): [PMID:8262389] |
| 6. Jang, L K LK and 5 more authors.. (2001) A novel leucine-rich repeat protein (LRR-1): potential involvement in 4-1BB-mediated signal transduction.. Molecules and cells, (31): [PMID:11804328] |
| 7. Saoulli, K K and 10 more authors.. (1998) CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.. The Journal of experimental medicine, (1): [PMID:9607925] |
